Clean Science and Technology Limited has released its investor presentation for the second quarter and half year ended September 30, 2026. The presentation highlights consolidated financial performance, P&L overview, balance sheet details, revenue profile, and key growth drivers. It details revenue growth supported by new segments, margin moderation due to geopolitical headwinds, and strategic initiatives such as capex in a subsidiary and new product commercialization.
Investor Presentation for Q2 FY2027 Released
Clean Science and Technology Limited has submitted its investor presentation for the quarter and half year ended September 30, 2026. This document provides a comprehensive overview of the company’s financial performance and strategic direction.
Financial Highlights
Q2 FY2027 Consolidated Performance
For the second quarter of FY2027, the company reported consolidated revenues of INR 299 crore, marking a 22% year-on-year increase. EBITDA stood at INR 92 crore with an EBITDA margin of 31.2%. Profit After Tax (PAT) was INR 56 crore, with a PAT margin of 18.9%.
H1 FY2027 Consolidated Performance
In the first half of FY2027, consolidated revenues reached INR 568 crore, a 16% year-on-year growth. EBITDA was INR 188 crore (33.7% margin), and PAT was INR 129 crore (23.1% margin).
Balance Sheet Overview (as at September 30, 2026)
The consolidated balance sheet shows total assets of INR 1,920 crore, with non-current assets at INR 967 crore and current assets at INR 953 crore. Net-worth stood at INR 1,672 crore, with total liabilities at INR 248 crore (non-current liabilities: INR 35 crore; current liabilities: INR 213 crore).
Business Updates and Growth Drivers
- CAPEX & Business Update: Approximately INR 150 crore was incurred in H1 FY2027 for investment in its wholly owned subsidiary, Clean Fino Chem Ltd. (CFCL).
- CFCL Progress: CFCL completed advanced HALS product trials and is expected to launch commercially in H2 FY2026-27.
- New Product Commercialization: Performance Chemical 2 is expected to be commercialized in H2 FY2027.
- Revenue Profile: The HALS segment grew 2x in H1 FY2027, now accounting for 22% of sales. The contribution of the top four legacy products has declined to 58%.
Key Differentiators and Strategy
The company emphasizes its strengths in Innovation, being Global Leaders in specialty chemicals, a Preferred Partner of Choice, and operating State-of-the-Art manufacturing facilities. Key growth drivers include a focus on ESG and Sustainability, strengthening its presence in India and globally, significant Greenfield Capex, New Product Development, and adding new competencies.
The presentation also details the company’s commitment to sustainability, robust corporate governance, advanced manufacturing capabilities, and a strong financial performance track record.
Source: BSE
